EMA committee recommends approval of Sanofi & Regeneron’s Dupixent to treat eosinophilic esophagitis in children as young as 1 year old: Paris Monday, September 23, 2024, 11:00 ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

Paris: Sanofi has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication.

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Vascular space involvement, venous or lymphatic, does not affect classification. ‡ The presence of bullous edema is not sufficient to classify a tumor as T4. Table 2. Studies Investigating the ...

Responding to rising mpox cases in Africa, the World Health Organization declared a public health emergency of international ...

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin.